Last reviewed · How we verify
Docetaxel - Cisplatine - 5FU
At a glance
| Generic name | Docetaxel - Cisplatine - 5FU |
|---|---|
| Sponsor | Recherche clinique |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT (PHASE3)
- Trial Evaluating Adapted Chemotherapy in Patients With Squamous Carcinoma (PHASE2)
- NESC: Neoadjuvant Treatment of Gastric Adenocarcinoma (PHASE2)
- Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer. (PHASE2)
- Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Docetaxel - Cisplatine - 5FU CI brief — competitive landscape report
- Docetaxel - Cisplatine - 5FU updates RSS · CI watch RSS
- Recherche clinique portfolio CI